open access

Ahead of print
Research paper
Published online: 2021-05-20
Get Citation

Harmful versus beneficial effects of using short-term combined oral antidiabetic therapy: ‎An open label comparative clinical trial ‎

Qoyama N Baito, Ansam N Alhassani, Marwan S Al-Nimer
DOI: 10.5603/DK.a2021.0033

open access

Ahead of print
Original articles (submitted)
Published online: 2021-05-20

Abstract

Background: Although oral antidiabetic drugs have many beneficial pleiotropic effects, they are ‎not free from adverse reactions that may interfere with glucose homeostasis. This study aimed ‎to assess the effects of oral antidiabetic drugs as add- on-therapy to metformin, on the metabolic, ‎cardiac, and renal determinants. ‎ Material and methods: A total number of seventy-eight type 2 diabetes (T2D) patients who ‎were treated with metformin were allocated to add-on-therapy for 12 weeks, with glimepiride ‎‎(4mg/day, n=26), sitagliptin (100mg/day, n=28), and canagliflozin (300mg/day, n=24). ‎Anthropometric measurements, glycemic indices, lipid, and renal markers, were determined ‎before initiation and after the treatment. ‎ Results: All of the three treatments significantly decreased the glycemic indices, triglyceride-to-glucose index, and non-significantly altered the serum uric acid-to creatinine. Glimepiride ‎significantly increased the waist-to-height ratio (0.630±0.057 versus 0.640±0.057, p=0.040), ‎while sitagliptin and canagliflozin significantly decreased it (0.650±0.058 versus 0.640±0.054, ‎p=0.009, and 0.650±0.041 versus 0.630±0.044, p<0.001). Estimated glomerular filtration index- ‎epidemiology collaboration (ml/min/1.73m2) significantly declined by using glimepiride ‎‎(109.0±10.4 versus 103.6±10.9, p=0.001), and sitagliptin (106.1±12.4 versus 103.3±15.0, ‎p=0.013). ‎ Conclusion: Careful selection of using oral antidiabetic agents can protect T2D patients from ‎harmful events, particularly those related to cardiovascular events and renal function‎

Abstract

Background: Although oral antidiabetic drugs have many beneficial pleiotropic effects, they are ‎not free from adverse reactions that may interfere with glucose homeostasis. This study aimed ‎to assess the effects of oral antidiabetic drugs as add- on-therapy to metformin, on the metabolic, ‎cardiac, and renal determinants. ‎ Material and methods: A total number of seventy-eight type 2 diabetes (T2D) patients who ‎were treated with metformin were allocated to add-on-therapy for 12 weeks, with glimepiride ‎‎(4mg/day, n=26), sitagliptin (100mg/day, n=28), and canagliflozin (300mg/day, n=24). ‎Anthropometric measurements, glycemic indices, lipid, and renal markers, were determined ‎before initiation and after the treatment. ‎ Results: All of the three treatments significantly decreased the glycemic indices, triglyceride-to-glucose index, and non-significantly altered the serum uric acid-to creatinine. Glimepiride ‎significantly increased the waist-to-height ratio (0.630±0.057 versus 0.640±0.057, p=0.040), ‎while sitagliptin and canagliflozin significantly decreased it (0.650±0.058 versus 0.640±0.054, ‎p=0.009, and 0.650±0.041 versus 0.630±0.044, p<0.001). Estimated glomerular filtration index- ‎epidemiology collaboration (ml/min/1.73m2) significantly declined by using glimepiride ‎‎(109.0±10.4 versus 103.6±10.9, p=0.001), and sitagliptin (106.1±12.4 versus 103.3±15.0, ‎p=0.013). ‎ Conclusion: Careful selection of using oral antidiabetic agents can protect T2D patients from ‎harmful events, particularly those related to cardiovascular events and renal function‎

Get Citation

Keywords

Type 2 diabetes; glimepiride; sitagliptin; canagliflozin

About this article
Title

Harmful versus beneficial effects of using short-term combined oral antidiabetic therapy: ‎An open label comparative clinical trial ‎

Journal

Clinical Diabetology

Issue

Ahead of print

Article type

Research paper

Published online

2021-05-20

DOI

10.5603/DK.a2021.0033

Keywords

Type 2 diabetes
glimepiride
sitagliptin
canagliflozin

Authors

Qoyama N Baito
Ansam N Alhassani
Marwan S Al-Nimer

References (29)
  1. Kalra S, Deepak MC, Narang P, et al. Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: results from OBSTACLE Hypoglycemia Study. Diabetes Technol Ther. 2013; 15(2): 129–135.
  2. Gu T, Ma J, Zhang Q, et al. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial. Diabetes Obes Metab. 2019; 21(4): 939–948.
  3. Zhu J, Yu X, Zheng Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. The Lancet Diabetes & Endocrinology. 2020; 8(3): 192–205.
  4. Petrica L, Petrica M, Vlad A, et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr. 2009; 121(23-24): 765–775.
  5. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013; 139(1): 51–59.
  6. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669–2701.
  7. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010; 70(4): 377–385.
  8. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4): 515–531.
  9. Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94(1): 26–39.
  10. Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016; 134(10): 752–772.
  11. Woo VC. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes. Can J Diabetes. 2020; 44(1): 61–67.
  12. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017; 77(2): 209–224.
  13. Zhou Yi, Guo Z, Yan W, et al. Cardiovascular effects of sitagliptin - An anti-diabetes medicine. Clin Exp Pharmacol Physiol. 2018; 45(7): 628–635.
  14. Mokta JK, Sahai AK, Kaundal PK, et al. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. J Assoc Physicians India. 2018; 66(8): 30–35.
  15. Mishriky BM, Tanenberg RJ, Sewell KA, et al. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018; 44(2): 112–120.
  16. Li M, Yang Yi, Jiang D, et al. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(39): e8161.
  17. Gibson S, Ashwell M. A simple cut-off for waist-to-height ratio (0·5) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England. Br J Nutr. 2020; 123(6): 681–690.
  18. Brito AD, Hermsdorff HH, Filgueiras MD, et al. Predictive capacity of triglyceride-glucose (TyG) index for insulin resistance and cardiometabolic risk in children and adolescents: a systematic review. Crit Rev Food Sci Nutr. 2020 [Epub ahead of print]: 1–10.
  19. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–612.
  20. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev. 2010; 23(2): 247–269.
  21. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015; 100(2): 363–370.
  22. Blonde L, Stenlöf K, Fung A, et al. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016; 128(4): 371–380.
  23. Davies MJ, Merton KW, Vijapurkar U, et al. Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Metab Syndr Obes. 2017; 10: 47–55.
  24. Kutoh E, Wada A, Kuto AN, et al. Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin. Hosp Pract (1995). 2021; 49(2): 71–78.
  25. Kutoh E, Wada A, Kuto AN, et al. Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function
. Int J Clin Pharmacol Ther. 2019; 57(12): 590–595.
  26. Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015; 17(4): 426–429.
  27. Cornel JH, Bakris GL, Stevens SR, et al. TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016; 39(12): 2304–2310.
  28. Heerspink HJL, Desai M, Jardine M, et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol. 2017; 28(1): 368–375.
  29. Rajani A, Sahay M, Bhattacharyya A, et al. Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE. Diabet Med. 2020; 37(4): 593–601.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl